|
Characteristics
|
Total (n = 790, 100.0%)
|
Newly diagnosed (n = 124, 15.7%)
|
Follow-up (n = 666, 84.3%)
|
P value
|
|---|
|
Age (SD), years
|
44.4 (13.1)
|
41.7 (13.0)
|
44.9 (13.1)
|
0.016
|
|
Ranges:
| | | | |
|
19-35 years
|
25.7%
|
36.8%
|
23.6%
|
0.025
|
|
36-50 years
|
40.8%
|
36.8%
|
41.7%
| |
|
51-65 years
|
26.0%
|
19.3%
|
27.2%
| |
|
> 65 years
|
7.4%
|
7.0%
|
7.5%
| |
|
Gender (female)
|
68.9%
|
63.7%
|
69.8%
|
NS
|
|
Diagnosis delay (SD), years
|
2.3 (4.9)
|
2.2 (4.6)
|
2.3 (5.0)
|
NS
|
|
Body mass index, kg/m2
|
24.8 (4.0)
|
24.2 (3.3)
|
25.0 (4.1)
|
0.018
|
|
Drug intake at time of the study visit (n):
| | | | |
|
Average
|
2.4 (1.2)
|
1.8 (1.2)
|
2.5 (1.2)
|
< 0.001
|
|
1
|
26.0%
|
55.4%
|
22.7%
|
< 0.001
|
|
2
|
33.3%
|
24.6%
|
34.3%
| |
|
3
|
21.3%
|
6.2%
|
23.0%
| |
|
4
|
14.5%
|
9.2%
|
15.1%
| |
|
5 or more
|
4.9%
|
4.6%
|
4.9%
| |
|
Drug intake at the time of the study visit (class):
| | | | |
|
Benzodiazepines
|
49.3%
|
72.9%
|
47.3%
|
< 0.001
|
|
SSRI/SNRI
|
34.9%
|
15.3%
|
36.6%
| |
|
Tricyclic antidepressants
|
9.2%
|
6.8%
|
9.5%
| |
|
Antiepileptics
|
2.8%
|
1.7%
|
2.9%
| |
|
Other medication
|
3.7%
|
3.4%
|
3.7%
| |
- Values are expressed as arithmetic mean (SD).
- NS = not significant; SSRI/SNRI = selective serotonin reuptake inhibitors/mixed action selective serotonin reuptake inhibitors or noradrenergics.
